# A Randomized, Double-blind, Active Control, Parallel Group, Titration, Multicenter Study to Evaluate the Efficacy and Safety of Fimasartan

Study · id `cardio:ct-nct02620306` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02620306](<https://clinicaltrials.gov/study/NCT02620306>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02620306

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 351 participants.

## Technical summary

Registry record NCT02620306. Randomized; quadruple masking; primary purpose treatment. Start 2016-02-11 (actual); primary completion 2019-12-23 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 351 participants (enrolled count; ClinicalTrials.gov record NCT02620306, source copy `cardio:ctgov-nct02620306-2022-05-25`, retrieved 2026-10-26)
- Started: 2016-02-11 (actual) (ClinicalTrials.gov record NCT02620306, source copy `cardio:ctgov-nct02620306-2022-05-25`, retrieved 2026-10-26)
- Primary completion: 2019-12-23 (actual) (ClinicalTrials.gov record NCT02620306, source copy `cardio:ctgov-nct02620306-2022-05-25`, retrieved 2026-10-26)
- Completion: 2022-05-11 (actual) (ClinicalTrials.gov record NCT02620306, source copy `cardio:ctgov-nct02620306-2022-05-25`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT02620306, source copy `cardio:ctgov-nct02620306-2022-05-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02620306-2022-05-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Randomized, Double-blind, Active Control, Parallel Group, Titration, Multicenter Study to Evaluate the Efficacy and Safety of Fimasartan
- Condition: Chronic Kidney Disease
- Intervention (Drug): Fimsartan 60mg~120mg
- Intervention (Drug): Fimsartan 60mg~120mg
- Intervention (Drug): Losartan 50mg~100mg
- Intervention (Drug): Losartan 50mg~100mg
- Lead sponsor: Boryung Pharmaceutical Co., Ltd
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Boryung Pharmaceutical Co., Ltd (`cardio:org-boryung-pharmaceutical-co-ltd`)

## Provenance

Content hash: 58b16b04b9773a8a8c9344a7015205dac779535581f7135f14650ec4b4348efb
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
